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Abstract: Depending on the initiating stimulus, cancer cell death can be immunogenic or
non-immunogenic. Inducers of immunogenic cell death (ICD) rely on endoplasmic reticulum
(ER) stress for the trafficking of danger signals such as calreticulin (CRT) and ATP. We found that
nanosecond pulsed electric fields (nsPEF), an emerging new modality for tumor ablation, cause the
activation of the ER-resident stress sensor PERK in both CT-26 colon carcinoma and EL-4 lymphoma
cells. PERK activation correlates with sustained CRT exposure on the cell plasma membrane and
apoptosis induction in both nsPEF-treated cell lines. Our results show that, in CT-26 cells, the activity
of caspase-3/7 was increased fourteen-fold as compared with four-fold in EL-4 cells. Moreover, while
nsPEF treatments induced the release of the ICD hallmark HMGB1 in both cell lines, extracellular
ATP was detected only in CT-26. Finally, in vaccination assays, CT-26 cells treated with nsPEF or
doxorubicin equally impaired the growth of tumors at challenge sites eliciting a protective anticancer
immune response in 78% and 80% of the animals, respectively. As compared to CT-26, both nsPEFand mitoxantrone-treated EL-4 cells had a less pronounced effect and protected 50% and 20% of the
animals, respectively. These results support our conclusion that nsPEF induce ER stress, accompanied
by bona fide ICD.
Keywords: ablation; immunotherapy; vaccine; apoptosis; electroporation

1. Introduction
Several local ablative therapies are available as innovative treatments to fight cancer. Although
both ablation and surgical resection result in the focal eradication of tumors, ablation causes cell death
in situ. By killing tumors locally, ablative therapies make tumor antigens available as an in situ cancer
vaccine which has the potential to initiate a systemic antitumor immune response.
Thermal ablation technologies such as radiofrequency ablation (RFA), microwave ablation (MWA),
and high intensity focused ultrasound (HIFU) have all been shown to elicit immunomodulatory
effects, the magnitude of which is highly variable [1]. While each modality accomplishes the local
deposition of energy via different approaches, all these ablation methods cause cell death via necrosis.
Accidental necrosis is a rapid cell death process which lacks morphological and biochemical changes
that are typically associated with late apoptosis and secondary necrosis [2]. Although in vitro damage
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associated molecular patterns (DAMPs) released from necrotic cells led to maturation of antigen
presenting cells (APCs), in vivo necrotic cell vaccines showed an immunologically inert nature which
did not protect animals from tumor challenge [3,4].
The potential of dead and dying cells to trigger an antitumor immune response depends on
the regulated emission of DAMPs, such as the endoplasmic reticulum protein calreticulin (CRT),
ATP, and the chromatin-binding protein high mobility group B1 (HMGB1). These signals are
crucial for immunogenic cell death (ICD). The extracellular release of HMGB1 and ATP attracts
and activates APCs, whereas CRT exposure on the surface of dying tumor cells serves as an “eat-me”
signal for phagocytes [5–7]. Collectively, these signals enhance APCs ability to engulf, process,
and present tumor-derived antigens to T-cells, thus favoring the induction of a tumor-specific adaptive
immunity [5,8,9].
Several studies have shown that the stress responses that precede cell death control the temporally
coordinated emission of DAMPs [5,6,10]. Among these stress responses, the central role for endoplasmic
reticulum (ER) stress has been revealed in all scenarios of ICD described thus far [11]. The endoplasmic
reticulum is a crucial organelle that controls Ca2+ -storage and buffering, lipid biosynthesis, and folding
and assembling of secretory and transmembrane proteins. Considering the relevance of maintaining
ER homeostasis, cells have developed an adaptation mechanism to rapidly sense and respond
to perturbations in the ER folding machinery, called the unfolded protein response (UPR) [11–13].
In mammalian cells, the UPR is controlled by three ER-resident stress sensors, namely, inositol-requiring
enzyme 1 alpha (IRE1α), activating transcription factor 6 (ATF6), and protein kinase R-like ER kinase
(PERK). When the ER stress is mild, the UPR facilitates the re-establishment of the cellular homeostasis.
However, when ER stress intensity is too severe, the UPR engages signaling pathways culminating
into cell death executed through the apoptotic program [11,12,14,15].
Considering the dependence of ICD on the induction of sustained ER stress, it is no surprise that
the ER stress intensity caused by an ICD inducer has a strong impact on the quality and quantity of
the emitted DAMPs. This led to the subdivision of ICD inducers into two categories, Type I and type
II. Type I ICD inducers, such as anthracyclines, oxaliplatin, and radiotherapy, trigger apoptotic cell
death which is accompanied by collateral ER-stress. Type II inducers, such as hypericin-photodynamic
therapy (Hyp-PDT) or oncolytic viruses, selectively targets the ER, inducing ER stress-dependent
apoptosis [10,16–18]. Among the three ER-stress sensors, PERK has been shown to have a predominant
role in mediating the trafficking of DAMPs. PERK regulates the externalization of CRT in response to
chemotherapy [7,19–21] and the emission of both CRT and ATP after Hyp-PDT [22]. Moreover, ablation
of PERK in cancer cells compromises ICD by suppressing its tumor-rejecting anticancer vaccination
effect in vivo [19].
Pulsed electric fields (PEF) compromise the integrity of the cell plasma membrane, a process
referred to as electroporation or electropermeabilization [23–25]. Conventional electroporation pulses
are relatively long (µs to ms) with lower electric fields (≤1 kV/cm) and they have been widely used
in many biomedical applications including in vitro cell transfection [26], in vivo gene transfer [27,28],
and intracellular delivery of cytotoxic agents such as bleomycin to kill tumors [29–32]. Ablation of
tumors can also be achieved by more intense PEF treatments which cause irreversible electroporation
(IRE) [33–35]. Treatment of tissue with PEF requires the application of electrodes to the area to be
treated and the delivery of PEF according to specific protocols. The treatment intensity (as determined
by the pulse amplitude, number, and duration) needs to be sufficiently high to destroy the cells, but not
too high in order to avoid the concurrent Joule heating and thermal damage.
Recently, PEF protocols have been extended to nanosecond-duration pulses (nsPEF). Unlike microand millisecond duration PEF, under specific conditions nsPEF have been shown to penetrate
the cell plasma membrane and permeabilize organelle membranes such as the ER, mitochondria,
and nucleus [36–41]. In the conventional electroporation, charging of the cell plasma membrane
compensates the external electric field and protects the cell interior. Characteristic charging time
constants for the plasma membrane of mammalian cells are in the order of 100 ns. However, for field
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magnitudes greater than 10 kV/cm, ultrashort nanosecond pulses can charge smaller intracellular
structures to the electroporation threshold faster than it would take for the plasma membrane to charge
and protect them [42–44]. Subsequent biological responses range from Ca2+ mobilization [39–41,45,46],
reactive oxygen species (ROS) production [47,48], rapid externalization of phosphatidylserine [49–51],
activation of the c-Jun N-terminal kinase 1 (JNK) [52], and mitogen-activated protein kinase (MAPK) [53]
pathways to the induction of apoptotic and necrotic cell death [37,54–57].
Cancer cell killing by nsPEF has been extensively explored in vitro [37,55,57–60] followed by
successful tumor ablation trials in vivo in animals [57,61–66] and humans [67].
In addition to the high ablation efficiency, several groups, including ours, have reported that
nsPEF elicit an antitumor immune response which, depending on the tumor model or pulse parameters,
protected 100% to 25% of the treated animals from tumor challenge [57,65,66,68–71]. The mechanisms
responsible for this inhibition remain poorly understood.
In this study, we investigated the efficacy of nsPEF treatment at inducing ER stress and ICD in
both immunogenic CT-26 colon carcinoma and poorly immunogenic EL-4 lymphoma cells. Our results
show that nsPEF activate PERK, accompanied by apoptotic cell death and emission of major DAMPs.
Moreover, nsPEF-treated CT26 and EL-4 tumor cells vaccinated 78% and 50% of the animals from
tumor challenge, respectively.
2. Results
2.1. nsPEF Induce ER-Stress in Cancer Cells
Because nsPEF have been shown to directly permeabilize the ER leading to a rise in cytosolic
[39,40] and to induce ROS production [47,48], we tested a hypothesis that nsPEF treatments could
trigger a generalized ER stress response in tumor cells.
In preliminary experiments we investigated the sensitivity to nsPEF of both immunogenic CT-26
and poorly immunogenic EL-4 cells and established 300 and 100 pulses (200 ns, 7 kV/cm, 10 Hz) as
iso-effective doses causing 60% cell death at 24 h, respectively. Using these pulse doses, we measured
the level of spliced XBP1 mRNA in both nsPEF-treated tumor cell lines. XBP1 is a key transcription
factor that regulates the UPR. Its expression is regulated by unconventional mRNA splicing that is
carried out by the ER-sensor IRE1 [72,73]. Figure 1A shows that in EL-4 cells (top panel) 200 ns pulses
did not induce an accumulation of spliced XBP1. Conversely, in CT-26 cells (bottom panel) nsPEF
increased the level of spliced XBP1 by five-fold.
During ICD, while all three sensors of the UPR are activated, only the PERK branch is so far
mandatory for ICD [19,21]. Therefore, we studied PERK activation in nanoporated cells. Our results
show that 200 ns pulses induce the activation of PERK in both cell lines as measured by the
phosphorylation of its substrate eukaryotic translation initiation factor 2α (eIF2α) on serine 51
(Figure 1B).
Overall our data show that nsPEF induce ER stress accompanied by PERK activation while the
IRE1 branch of the UPR response appear to be activated in a cell type-specific manner.
Ca2+
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Previous studies have shown that PERK activation and the phosphorylation of its substrate eIF2α
are essential for CRT exposure induced by anthracyclines, oxaliplatin, and Hyp-PDT [19,22]. Therefore,
we investigated whether PERK activation correlated with CRT exposure on the plasma membrane of
nanoporated tumor cells. Figure 3 shows that nsPEF triggered CRT translocation in both EL-4 (Figure 3A)
and CT26 (Figure 3B). Notably, the efficiency of nsPEF at inducing CRT relocalization to the cell plasma
membrane was comparable or even higher than the effect of the positive control mitoxantrone.
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experiments. CT26 and EL-4 cells were treated with 600 and 200 pulses (200 ns, 7 kV/cm, 10 Hz),
of major DAMPs. The capacity of nsPEF to induce bona fide ICD was finally tested in standard
respectively, and in order to allow ICD to occur in vivo, immediately injected in syngeneic mice.
vaccination experiments. CT26 and EL-4 cells were treated with 600 and 200 pulses (200 ns, 7 kV/cm,
Figure 2B shows that for both cell lines, even at the highest pulse doses, cell death leveled off to 80% to
10 Hz), respectively, and in order to allow ICD to occur in vivo, immediately injected in syngeneic
85%. These results are consistent with previous studies showing that exposures of suspension cells in
mice. Figure 2B shows that for both cell lines, even at the highest pulse doses, cell death leveled off
electroporation cuvettes do not result in 100% cell killing [55,58,60]. Although treated with a vaccine
to 80% to 85%. These results are consistent with previous studies showing that exposures of
containing 15% to 20% live cells, tumors at vaccination sites did not develop in 60% (nine out of fifteen)
suspension cells in electroporation cuvettes do not result in 100% cell killing [55,58,60]. Although
and 25% (six out twenty-five) of CT-26 and EL-4 syngeneic mice, respectively. The difference between
treated with a vaccine containing 15% to 20% live cells, tumors at vaccination sites did not develop
the two models may reflect their intrinsic immunogenicity with CT-26 being more immunogenic than
in 60% (nine out of fifteen) and 25% (six out twenty-five) of CT-26 and EL-4 syngeneic mice,
EL-4 cells [75,76]. In animals that did not develop tumors at the vaccination site, CT26 cells treated
respectively. The difference between the two models may reflect their intrinsic immunogenicity with
with nsPEF and doxorubicin equally impaired the growth of tumors at challenge sites (Figure 5A)
CT-26 being more immunogenic than EL-4 cells [75,76]. In animals that did not develop tumors at the
eliciting a protective anticancer immune response in 78% (seven out of nine) and 80% (eight out of
vaccination site, CT26 cells treated with nsPEF and doxorubicin equally impaired the growth of
ten) of the animals, respectively (Figure 5B). Among animals with tumors at the primary injection site,
tumors at challenge sites (Figure 5A) eliciting a protective anticancer immune response in 78% (seven
five out of six developed tumors also at challenge sites, yet these tumors grew significantly slower
out of nine) and 80% (eight out of ten) of the animals, respectively (Figure 5B). Among animals with
(Supplementary Figure S1). Compared to CT-26, nsPEF-treated EL-4 cells had a less pronounced
tumors at the primary injection site, five out of six developed tumors also at challenge sites, yet these
effect and protected 50% (three out of six) of the animals (Figure 6A). Notably, both 0.5 and 1 µM
tumors grew significantly slower (Supplementary Figure S1). Compared to CT-26, nsPEF-treated ELmitoxantrone-treated cells failed to induce an effective antitumor immune response in EL-4 syngeneic
4 cells had a less pronounced effect and protected 50% (three out of six) of the animals (Figure 6A).
Notably, both 0.5 and 1 µM mitoxantrone-treated cells failed to induce an effective antitumor
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3. Discussion
In this study we show that nsPEF stimulate an anticancer immune response via induction of ICD.
Although Nuccitelli et al. [71] have previously reported the effect of nsPEF on DAMPs emission, this is
the first comprehensive study investigating ICD induction in nanoporated tumor cells. According to
Kepp et al. [77], we measured apoptosis, ER stress, CRT exposure, ATP secretion, and HMGB1 release
and proved the ICD-inducing capacity of nsPEF in standard vaccination assays in immunocompetent
and syngeneic mouse models.
Our results show that nsPEF can induce the phosphorylation of eIF2α in both CT26 and EL-4
tumor cells. The eIF2α phosphorylation is the hallmark of the integrated stress response (IRS),
a complex signaling pathway that is activated in response to both cell extrinsic factors such as hypoxia,
amino acid and glucose deprivation, viral infections, and cell intrinsic stresses such as ER stress [78].
Four distinct specific kinases, namely, PERK, double-stranded RNA-dependent protein kinase (PKR),
heme-regulated eIF2α kinase (HRI), and general control non-derepressible 2 kinase (GCN2) can
catalyze eIF2α phosphorylation [78]. However, in the context of ICD, it is the ER stress sensor PERK
that phosphorylates eIF2α [19,21,22]. Moreover, Morotomi-Yano et al. have previously reported that,
in HeLa cells, both PERK and GCN2 contribute to nsPEF-induced eIF2α phosphorylation causing a
block in protein translation [79].
Our results also show that, in CT26 cells, nsPEF trigger a more generalized ER stress response by
activating both IRE1 and PERK, whereas, in EL-4 cells, nsPEF fail to activate IRE1. Notably, as reported
by Morotomi-Yano et al., IRE1 was also not activated in nanoporated HeLa cells. Moreover, the same
study reported that nsPEF-induced eIF2α phosphorylation did not stimulate the expression of its main
downstream transcription factors, namely, activating transcription factor 4 (ATF4) and CHOP [79].
Although surprisingly, these results are in agreement with the recent study from Bezu et al. who
reported that the ICD inducers mitoxantrone, doxorubicin, and oxaliplatin cause PERK-mediated
eIF2α phosphorylation but are unable to induce IRE-mediated splicing of XBP1 and fail to stimulate
ATF4 and CHOP expression [21]. These data suggest that an incomplete ER stress response is enough
to induce ICD, although, in certain tumor cell lines, nsPEF can engage more arms of this response.
Considering these results, a key question to consider is how nsPEF trigger ER stress. Perturbations
in cellular energy, Ca2+ homeostasis or redox status can all cause ER stress and PERK activation.
Because nanosecond pulses are distinguished by their ability to permeabilize the ER and recruit Ca2+
from intracellular stores [39–41,45,46], one can speculate that nsPEF can cause ER Ca2+ depletion.
Notably, thapsigargin, a pharmacological antagonist of sarcoplasmic/endoplasmic reticulum Ca2+
ATPase (SERCA), the pump that moves Ca2+ into the ER, causes ER stress by draining the Ca2+ ER
storage. This depletion decreases the activity of Ca2+ -dependent chaperones leading to an increase in
unfolded proteins and activation of the UPR signaling [12].
Most ICD stimuli including anthracyclines, UVC radiation, and Hyp-PDT trigger ROS-dependent
ER stress. For instance, in Hyp-PDT, hypericin accumulates preferentially within the membranes of
the ER [80] and its photoactivation generates ROS [81]. These short-lived species act locally on ER
membrane phospholipids [82]. Lipid peroxidation can lead to inactivation of receptors and proteins
such as SERCA during Hyp-PDT [83–85]. Because PEF, including nsPEF, have been found to increase
the level of ROS in the cell [47,86,87], one could hypothesize that electroporation can induce ER stress
through mechanisms similar to Hyp-PDT. nsPEF exposure was shown to damage mitochondria causing
leakage of ROS and cytochrome C [37]. Moreover, electropermeabilization is accompanied by lipid
peroxidation, as previously shown in both mammalian cells and liposomes [88–92].
In our study we show that the capacity of nsPEF to engage more arms of the ER stress response
can affect the quality and quantity of emitted DAMPs. Indeed, while nsPEF trigger CRT externalization
in both CT26 and EL-4, ATP was detectable only in the supernatant of nanoporated CT26 cells.
Previous studies have reported that electroporation causes leakage of ATP through the pores [93].
However, in CT26 ATP release was detected 18 h after nsPEF exposure, suggesting the engagement
of active mechanisms for ATP secretion in nanoporated tumor cells. Active ATP release in response
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to ICD inducers was shown to be dependent on autophagy [6], a catabolic process evolved to
maintain the homeostasis of proteins and damaged organelles. Recently autophagy has emerged as an
essential protective mechanism during ER stress and IRE1-mediated JNK phosphorylation appears
to be a major regulator in this pathway. Specifically, IRE1 activation leads to JNK phosphorylation,
which in turn regulates the autophagy related protein Beclin-1 (BECN1). The activation of BECN1
is followed by direct phosphorylation of B-cell lymphoma 2 (BCL2), which in turn disrupts the
interaction between BECN1 and BCL2 and induces autophagy in tumor cells [94]. In addition
to the kinase activity, the endoribonuclease activity of IRE1 also participates in the induction of
autophagy. Spliced XBP1 binds directly to the BECN1 promoter supporting an autophagic response
via transcriptional upregulation of BECN1 [95]. Altogether, these evidences suggest that the capacity
to activate IRE1 can affect autophagy-dependent ATP secretion in nanoporated tumor cells. Indeed,
although autophagy was not investigated, our results show that ATP secretion correlates with IRE1
activation by nsPEF in CT26 cells. Moreover, nsPEF can induce autophagy, as shown by Ullery et al.,
in both human lymphoma U937 and Chinese Hamster Ovarian-K1 (CHO-K1) cells [96].
The discrepancy in ATP detection in the supernatant of nanoporated CT26 and EL-4 cells can
also reflect a different expression level of ATP-degrading ectoenzymes. Tumor cells are proficient
at converting ATP into adenosine through the expression of ectonucleotidases such as CD39 and
CD73 [97]. To support this hypothesis, our results show that even in response to positive controls such
as doxorubicin, the level of ATP secretion was markedly higher in CT26 than in EL-4 cells.
In addition to ER stress, apoptotic cell death was shown to be crucial for ICD [98]. Our study
shows that nsPEF triggered apoptotic cell death in CT26 and EL-4, although to a different extent, in
CT-26 cells the activity of caspase-3/7 increased fourteen-fold as compared with four-fold in EL-4 cells.
Several studies have shown that nsPEF can trigger intrinsic, mitochondria-mediated, apoptotic cell
death [99,100]. Notably, in the case of unresolved ER stress, both PERK and IRE1 arms of the UPR can
engage the mitochondrial apoptotic machinery. Regarding PERK, phosphorylation of eIF2α favors
the translation of ATF4 which in turn induces the expression of the proapoptotic factor CHOP [101].
Concerning IRE1, prolonged activation of JNK induces apoptosis by dissociating BCL2 Associated
X (BAX) from BCL2 leading to BAX activation [102]. Although the mechanisms through which the
UPR integrates pro-death and pro-survival signals are poorly understood, one can speculate that
the capacity of nsPEF to engage more arms of the ER stress response may determinate the extent of
apoptosis induction in nanoporated tumor cells.
From the above discussion it appears that different tumor cell types can respond differently to
nsPEF. This could be related to the extent of ROS formation or permeabilization of the ER achieved
by the pulse treatment in a specific tumor cell type. Indeed, CT26 are more resistant to nsPEF than
EL-4, suggesting that the higher doses needed to kill colon carcinoma cells could have triggered stress
responses and cell death pathways which are not activated at lower pulse doses. In addition to the
intensity of the pulse treatment, genetic or epigenetic alterations that compromise stress responses or
cell death signaling pathways can also affect ICD induction by nsPEF.
A challenge in our vaccination experiments was the inability to achieve complete cell killing
in vitro. This failure to reach 100% cell death was previously explained by possible nonuniform electric
field exposure of cells at the edges of the cuvette and in the suspension meniscus, or by possible
shielding of some cells by other cells, as well as by an unusual level of resistivity to nsPEF in a limited
subpopulation of cells [55,58,60]. In our experimental conditions, tumor cell vaccines contained 0.09 to
0.12 × 106 (15% to 20%) live cells. Although the residual live cells in the vaccine were more than enough
to establish a tumor (more than the cells used to challenge the animals), tumors at the vaccination site
did not develop in 60% and 25% of CT26 and EL-4 syngeneic mice, respectively. These results challenge
the recent study from Sulciner et al. where in multiple tumor models, including EL-4 cells, tumor cells
killed by chemotherapy (cisplatin, vincristine, gemcitabine, or docetaxel) or targeted therapy (erlotinib
or cetuximab) and co-injected with a subthreshold inoculum of live cells dramatically stimulated
primary tumor growth [103]. Remarkably, none of the drugs used in the study were ICD inducers
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which, together with our results, suggests that the occurrence of ICD can overwhelm and counteract
the cancer promoting effects of dying tumor cells. Considering the above discussion, what we initially
believed to be a limitation for the vaccination study turned out to be an additional evidence that
nsPEF-induced cell death is perceived by the immune system as immunogenic.
4. Materials and Methods
4.1. Cell Culture and Reagents
Both mouse EL-4 lymphoma and B16F10 melanoma cells were acquired from ATCC (ATCC,
Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle medium (DMEM, Corning, Corning,
NY, USA). CT26 colon carcinoma cells (ATCC) were cultured in RPMI 1640 (Corning). Culture media
were supplemented with L-glutamine (ATCC), 10% fetal bovine serum (Atlanta Biologicals, Norcross,
GA, USA), 100 U/mL penicillin and 0.1 mg/mL streptomycin (Gibco, Gaithersburgh, MD, USA).
Thaspigargin (1 µM), mitoxantrone (0.5–1 µM), doxorubicin (10–25 µM), and staurosporin (10 µM)
were all from Sigma (Sigma-Aldrich, St. Louis, MO, USA).
4.2. Pulsed Electric Field Exposure Methods
Cell samples were resuspended at 1.2 to 3 × 106 cell/mL in the growth medium or PBS and loaded
in 1 mm gap electroporation cuvettes (BioSmith, San Diego, CA, USA). Samples were subjected to
either nsPEF or sham exposure at room temperature (22 ± 2 ◦ C). Trains of 200 ns pulses were delivered
to cuvettes from an AVTECH AVOZ-D2-B-ODA generator (AVTECH Electrosystems, Ottawa, Ontario,
Canada). Samples were exposed to up to 600, 200 ns, 7 kV/cm pulses at 10 Hz. Sample heating was
measured for the highest pulse dose (600, 200 ns, 7 kV/cm, 10 Hz) using a thermocouple thermometer
(Physitemp, Clifton, NJ, USA). By the end of PEF exposure, the measured values averaged 0.42 +/− 0.11.
Once exposure was completed, cells were seeded in 96, 24, or 6 well plates and placed at 37 ◦ C in
the incubator for the different incubation times (4 to 24 h).
4.3. Viability and Caspase-3/7 Activity Assays
Viability was measured at 4 and 24 h after nsPEF treatment using the resazurin-based metabolic
assay Presto Blue (Life Technologies, Grand Island, NY, USA). Plates were read with a Synergy 2
microplate reader, with excitation/emission settings at 530/590 nm.
In certain experiments, concurrently with cell viability, caspase-3/7 activity was measured. We first
recorded fluorescence (Presto Blue/viability) and, then, added the Caspase-Glo 3/7 assay (Promega
Corporation, Madison, WI, USA) according to manufacturer’s instructions.
Samples were measured in triplicates, the data were averaged, corrected for the background,
and considered as a single experiment.
4.4. RT-PCR and Western Blot
The RT-PCR procedure was described in detail previously [51]. Gene expression analysis was
conducted using TaqMan Gene Expression Assays for spliced XBP1 (Mm03464496_m1) [104] and the
endogenous housekeeping gene HPRT (Mm03024075_m1). Relative fold-changes were calculated
using the 2−∆∆Ct method. Significance was determined by comparing the 2−∆Ct value using a one-way
analysis of variance with a Dunnett’s post hoc test. Error bars represent the standard deviation of the
relative-fold expression between samples.
For Western blot, membranes were blocked in TBS 5% BSA buffer for 1 h at room temperature.
Primary rabbit anti-phospho-eIF2α (Serine 51) and rabbit anti-eIF2α antibodies and secondary
anti-rabbit IgG HRP were from Cell Signaling (Cell Signaling Technology, Danvers, MA USA).
Rabbit anti-vinculin was from Abcam (Abcam, Cambridge, UK). Antibodies were diluted in TBS,
5% BSA, 0.2% Tween buffer according to the manufacturer’s instructions. The membranes were
incubated overnight at +4 ◦ C and for 1 h at room temperature with primary and secondary antibodies,
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respectively. Membranes were imaged using a ChemiDoc MP imaging system (BioRad, Hercules, CA,
USA). Blot images in Figure 1 have been cropped, full-length blots are presented in Supplementary
Figure S2.
4.5. DAMPs Detection
Cell membrane CRT was measured at 24 h post nsPEF by flow cytometry using a rabbit polyclonal
anti-CRT antibody (Abcam) and a secondary goat anti-rabbit IgG (H + L) 488 (Invitrogen, Carlsbad, CA,
USA). Dead cells staining positive for DAPI were excluded from the analysis. Samples were acquired
using a MACSQuant Analyzer 10 flow cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany) and
analyzed with FlowJo software (FlowJo, Ashland, OR, USA).
HMGB1 was measured at 24 h post treatment by ELISA according to manufacturer’s instructions
(IBL International, Hamburg, Germany). ATP was measured at 18 h post nsPEF using the ENLITEN ATP
assay according to manufacturer’s instructions (Promega). Plates were read with a Synergy 2 microplate
reader. Samples were measured in triplicates, averaged, and considered as a single experiment.
4.6. Vaccination Experiments
Typically, millions of dead cells are used in vaccination experiments, however these numbers are
not feasible when using 1 mm electroporation cuvette to kill tumor cells. In preliminary experiments
aimed at optimizing the conditions for our vaccination experiments, we established that 0.6 × 106
doxorubicin treated CT26 cells were enough to vaccinate a mouse by a challenge dose of 0.1 × 106 live
cells. For the poorly immunogenic EL-4 model we decided to keep 0.6 × 106 dead cells for the vaccine
but to lower the challenge dose to the minimum number of cells needed to establish an EL-4 tumor,
which we found to be 0.03 × 106 cells.
Both CT26 and EL-4 cells were resuspended at 3 × 106 /mL in PBS and aliquoted into the
electroporation cuvettes (about 3 cuvettes/animal). Immediately after the treatment, all samples were
pooled together, cells were counted, centrifuged, resuspended at 6 × 106 /mL in PBS and injected in vivo
in syngeneic mice (100 µL mouse).
As a positive control for ICD induction, CT26 and EL-4 cells were treated with doxorubicin (25 µM)
and mitoxantrone (0.5 and 1 µM), respectively. After 24 h, cells were washed three times with PBS,
resuspended similarly to nsPEF treated cells and injected in vivo.
After one week, animals were challenged into the opposite flank with either 0.1 × 106 CT26
or 0.03 × 106 EL-4 live cells and monitored for the appearance of palpable tumors on both flanks.
Tumors were measured twice weekly using a caliper. The formula v = ab2 π/6 was used to calculate
tumor volumes where a is the longest diameter and b is the diameter perpendicular to a.
Seven- to 8-week-old C57/BL6 and BalbC female mice (Jackson Laboratory, Bar Harbor, ME,
USA) were housed in individually ventilated cages in groups of 5 under pathogen-free conditions.
All procedures were carried out in accordance with the Guide for the Care and Use of Laboratory
Animals, Eighth Edition and were approved by the Old Dominion University Institutional Animal
Care and Use Committee (permit number: 18-018).
4.7. Statistical Analysis
Data are presented as mean ± standard error for n independent experiments. Statistical analyses
were performed using a two-tailed t test where p < 0.05 was considered statistically significant.
Statistical calculations were accomplished using Grapher 11 (Golden Software, Golden, CO, USA).
5. Conclusions
Altogether, we have demonstrated that nsPEF induce ER stress accompanied by ICD. Future
research should focus on tailoring the pulse treatment to boost the immunogenicity of tumor cell death
across multiple tumor cell types.
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